Xeris Biopharma (XERS) Set to Announce Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Xeris Biopharma to post earnings of $0.0317 per share and revenue of $101.68 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. On average, analysts expect Xeris Biopharma to post $0.07 EPS for the current fiscal year and $0.30 EPS for the next fiscal year.

Xeris Biopharma Trading Down 5.0%

Xeris Biopharma stock opened at $10.17 on Tuesday. Xeris Biopharma has a 52 week low of $5.25 and a 52 week high of $11.41. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -92.45 and a beta of 0.53. The company has a 50 day moving average price of $9.34 and a 200 day moving average price of $7.53.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total value of $47,050.00. Following the transaction, the insider directly owned 1,351,053 shares of the company’s stock, valued at approximately $12,713,408.73. This represents a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.41, for a total transaction of $156,827.06. Following the completion of the transaction, the insider directly owned 1,111,130 shares in the company, valued at $10,455,733.30. This trade represents a 1.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 103,332 shares of company stock worth $948,871. 4.35% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on XERS. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Leerink Partners lifted their price target on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Finally, Barclays upped their price target on Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, October 6th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.20.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.